India’s Ramky Infrastructure will invest 300 billion rupees to develop a 1,000-hectare life sciences city. The project will be carried out through a public-private partnership (PPP), and Ramky has secured operating rights for a total of 95 years, including a five-year constructio
2026-05-06
Yungjin Pharm recorded an operating loss of 1.7 billion won in the first quarter of this year, swinging to a loss from a profit of 2.6 billion won in the same period a year earlier. Revenue during the period was 63.7 billion won, down 0.5% from a year earlier, while net loss was
2026-05-06
SK Bioscience reported an operating loss of 44.5 billion won in the first quarter, widening its deficit despite a 9% increase in revenue. The company’s consolidated first-quarter revenue totaled 168.6 billion won, up 9.1% from the same period a year earlier, while its operating l
2026-05-06
OpenAI’s AI model “o1” recorded diagnostic accuracy up to 17 percentage points higher than that of physicians in a blinded test conducted in an actual emergency department. The study, published in Science, found that AI’s advantage was more pronounced in the early stages, when in
2026-05-06
A new mechanism in which the oncogenic HER3 receptor functions as an inactive “reservoir” has been reported in Cell. Using photostable nanoparticles to track single molecules for more than 15 minutes, researchers identified HER3 homodimers for the first time. The findings provide
2026-05-06
Celltrion Pharm reported preliminary first-quarter 2026 revenue of 132.1 billion won and operating profit of 12.9 billion won. Revenue increased 17% and operating profit rose 20% from the same period a year earlier, while net income reached 8.8 billion won, up 20%. The results ar
2026-05-06
A three-drug combination for patients with intracerebral hemorrhage reduced the risk of recurrent intracerebral hemorrhage by 60% and the overall rate of recurrent stroke by 39%, according to study findings. The drug combines low doses of telmisartan, amlodipine and indapamide in
2026-05-06
Samsung Bioepis’ immuno-oncology drug Keytruda biosimilar SB27 met its primary endpoint in a phase 1 clinical trial involving 163 patients. The trial compared the pharmacokinetic equivalence of SB27 and the reference product in patients with non-small cell lung cancer, with treat
2026-05-06
The Mediterranean diet was found to reduce the risk of recurrence in patients with myocardial infarction by 50% to as much as 70%. The mechanism involves platelet-activating factor (PAF) inhibitors, which are abundant in foods such as olive oil and fish and suppress the inflammat
2026-05-06
STgenBio will expand its biosimilar contract manufacturing facility with an 85 billion won low-interest loan from the National Growth Fund. The investment will increase the maximum production capacity for drug substance (DS) and drug product (DP) by 44% and 170%, respectively. Th
2026-05-06
